Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Teva Branded Pharmaceutical Products R&D, Inc.
Michel D Ferrari; Hans Christoph Diener; Xiaoping Ning; Maja Galic; Joshua M Cohen; Ronghua Yang; Matthias Mueller; Andrew H Ahn; Yael Carmeli Schwartz; Melissa Grozinski-Wolff; Lindsay Janka; Messoud Ashina